Novartis isn’t messing around with CAR-T, and it has a promising next-gen therapy to help prove it
The center ring at ASCO this weekend will feature CTL019, Novartis’ lead CAR-T that appears to be headed to a landmark approval in a matter of months. But the pharma giant will also be putting the spotlight on a next-gen CAR-T therapy — CTL119 — with a compelling glimpse at its promise of improving reengineered cells’ persistence, amping up their therapeutic potential.
This new model CAR is made with a humanized CAR protein with, presumably, greater affinity to human proteins than the mouse proteins used in the first wave of CARs built at the University of Pennsylvania.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.